Abstract
Breast and ovarian cancers remain a major public health issue, constituting a major cause of female morbidity and mortality worldwide. Even though systemic chemotherapy remains the main course of action for both types of cancer, current research studies aim at the discovery of novel therapeutic targets. Ribonucleases, due to their apparent implication in gene expression regulation, may serve as potential anticancer drugs. Human RNase κ is an endoribonuclease belonging in a recently identified family of proteins. Recent data from expression microarray studies reveal that the RNase κ gene is found either up- or downregulated in a number of human cancers, indicating a possible diagnostic and/or prognostic utility.The aim of this study was to investigate modulations in the expression levels of RNase κ gene, in breast and ovarian cancer cells, as a response to treatment with different chemotherapeutic agents. BT-20 breast cancer cells and SKOV-3 ovarian cancer cells were treated with the cytotoxic drugs paclitaxel, docetaxel, cisplatin, carboplatin, epirubicin and vinorelbine. Gene expression analysis was performed by the comparative CT method also known as 2–ΔΔCT method. The results revealed a distinct increase in the expression levels of RNase κ mRNA (up to 9-fold) after treatment with the antineoplastic agent paclitaxel in both cell lines, while treatment with the remaining anticancer drugs did not alter drastically the mRNA levels of RNase κ. Based on the fact that paclitaxel exerts its cytotoxic action by inducing apoptosis, the results could be indicative of a potential implication of RNase κ in apoptosis-related pathways.
Keywords: BT-20, carboplatin, cisplatin, docetaxel, epirubicin, paclitaxel, RNase κ, SKOV-3, vinorelbine.
Anti-Cancer Agents in Medicinal Chemistry
Title:Effect of Cytostatic Drugs on the mRNA Expression Levels of Ribonuclease κ in Breast and Ovarian Cancer Cells
Volume: 14 Issue: 3
Author(s): Asimina S. Gkratsou, Emmanuel G. Fragoulis and Diamantis C. Sideris
Affiliation:
Keywords: BT-20, carboplatin, cisplatin, docetaxel, epirubicin, paclitaxel, RNase κ, SKOV-3, vinorelbine.
Abstract: Breast and ovarian cancers remain a major public health issue, constituting a major cause of female morbidity and mortality worldwide. Even though systemic chemotherapy remains the main course of action for both types of cancer, current research studies aim at the discovery of novel therapeutic targets. Ribonucleases, due to their apparent implication in gene expression regulation, may serve as potential anticancer drugs. Human RNase κ is an endoribonuclease belonging in a recently identified family of proteins. Recent data from expression microarray studies reveal that the RNase κ gene is found either up- or downregulated in a number of human cancers, indicating a possible diagnostic and/or prognostic utility.The aim of this study was to investigate modulations in the expression levels of RNase κ gene, in breast and ovarian cancer cells, as a response to treatment with different chemotherapeutic agents. BT-20 breast cancer cells and SKOV-3 ovarian cancer cells were treated with the cytotoxic drugs paclitaxel, docetaxel, cisplatin, carboplatin, epirubicin and vinorelbine. Gene expression analysis was performed by the comparative CT method also known as 2–ΔΔCT method. The results revealed a distinct increase in the expression levels of RNase κ mRNA (up to 9-fold) after treatment with the antineoplastic agent paclitaxel in both cell lines, while treatment with the remaining anticancer drugs did not alter drastically the mRNA levels of RNase κ. Based on the fact that paclitaxel exerts its cytotoxic action by inducing apoptosis, the results could be indicative of a potential implication of RNase κ in apoptosis-related pathways.
Export Options
About this article
Cite this article as:
Gkratsou S. Asimina, Fragoulis G. Emmanuel and Sideris C. Diamantis, Effect of Cytostatic Drugs on the mRNA Expression Levels of Ribonuclease κ in Breast and Ovarian Cancer Cells, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (3) . https://dx.doi.org/10.2174/18715206113139990090
DOI https://dx.doi.org/10.2174/18715206113139990090 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stathmin, Interacting with Nf-κB, Promotes Tumor Growth and Predicts Poor Prognosis of Pancreatic Cancer
Current Molecular Medicine Up-regulated Circulating miR-106a by DNA Methylation Promised a Potential Diagnostic and Prognostic Marker for Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Nano Approaches to Enhance Pharmacokinetic and Pharmacodynamic Activity of Plant Origin Drugs
Current Nanoscience Editorial [Hot Topic: Anticancer Platinum Complexes - State of the Art and Future Prospects (Guest Editor: Markus Galanski)]
Anti-Cancer Agents in Medicinal Chemistry New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Regulatory Circuitries Coordinated by Transcription Factors and microRNAs at the Cornerstone of Hematopoietic Stem Cell Self-Renewal and Differentiation
Current Stem Cell Research & Therapy Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors
Current Pharmaceutical Biotechnology ETS Proteins and MMPs: Partners in Invasion and Metastasis
Current Drug Targets Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists
Current Drug Delivery Small Molecules Modulating Biogenesis or Processing of microRNAs with Therapeutic Potentials
Current Medicinal Chemistry The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design Antiangiogenic Therapy
Current Pharmaceutical Design Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Editorial [Hot Topic: Anticancer Macromolecular Prodrugs in Clinical Trials - an Update (Guest Editor: Felix Kratz)]
Current Bioactive Compounds Mammaglobin-Based Strategies for Treatment of Breast Cancer
Current Cancer Drug Targets Malignant Pleural Mesothelioma in 2011. Is there a Gold Standard Therapy?
Current Respiratory Medicine Reviews The Role of Bone Density Measurements in the Evaluation of New Treatments for Osteoporosis
Current Pharmaceutical Design Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update
Current Cancer Drug Targets Application of Nanotechnology in the Diagnosis and Therapy of Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery